Adial Pharmaceuticals (ADIL) Proxy filing summary

Executive summary

• 2026 annual meeting adjourned again on Oct. 1 because Nasdaq approval of the listing application remained pending; proposals 3–6 are scheduled for Oct. 15.

Voting matters and shareholder proposals

• Proposals 1, 2, and 7–12 were voted on at the earlier meeting; voting on proposals 3–6 remains open, with no changes to the proposals.

• The meeting will reconvene Oct. 15, 2026, at 8:30 a.m. ET in Charlottesville, Virginia; the Aug. 17 record date remains in effect.

• Stockholders who already submitted proxies on proposals 3–6 need not act unless they want to change their votes.

Shareholder rights and capital structure

• The proxy solicitation concerns the adjourned annual meeting; stockholders were urged to review the definitive proxy statement and related SEC filings before voting.